Affordable Access

Access to the full text

Emerging Role of the NLRP3 Inflammasome and Interleukin-1β in Neonates

Authors
  • Omer, Murwan
  • Melo, Ashanty Maggvie
  • Kelly, Lynne
  • Mac Dermott, Emma Jane
  • Leahy, Timothy Ronan
  • Killeen, Orla
  • Saugstad, Ola Didrik
  • Savani, Rashmin C.
  • Molloy, Eleanor J.
Type
Published Article
Journal
Neonatology
Publisher
S. Karger AG
Publication Date
Oct 19, 2020
Volume
117
Issue
5
Pages
545–554
Identifiers
DOI: 10.1159/000507584
PMID: 33075792
Source
Karger
Keywords
License
Green
External links

Abstract

Infection and persistent inflammation have a prominent role in the pathogenesis of brain injury and cerebral palsy, as well as other conditions associated with prematurity such as bronchopulmonary dysplasia. The NLRP3 inflammasome-interleukin (IL)-1β pathway has been extensively studied in adults and pre-clinical models, improving our understanding of innate immunity and offering an attractive therapeutic target that is already contributing to clinical management in many auto-inflammatory disorders. IL-1 blockade has transformed the course and outcome of conditions such as chronic infantile neurological, cutaneous, articular (CINCA/NOMID) syndrome. Inflammasome activation and upregulation has recently been implicated in neonatal brain and lung inflammatory disease and may be a novel therapeutic target.

Report this publication

Statistics

Seen <100 times